CompanySLGLNasdaqNess Ziona

Sol-Gel Technologies Ltd.

Sol-Gel Technologies develops topical therapies for dermatological conditions.

SEC EDGAR ClinicalTrials.gov sol-gel.com

6-KSep 30Latest SEC filing

Sep 17Latest story

September 2026

Sol-Gel completes patient follow-up in Gorlin syndrome Phase 3 trial

Sep 17Clinical readoutpatidegib Sol-Gel Technologies Ltd.

August 2026

Sol-Gel reports Q2 2026 results, SGT-610 Phase 3 readout on track for late November

Aug 20Clinical readoutpatidegib Sol-Gel Technologies Ltd.

July 2026

Sol-Gel posts terminated Phase 2 patidegib gel trial results; 2 of 47 had serious adverse events

Jul 21Trial updatepatidegib Sol-Gel Technologies Ltd.